Inhibrx Biosciences (INBX) Share-based Compensation (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Share-based Compensation for 3 consecutive years, with $2.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Share-based Compensation fell 8.01% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $8.0 million (down 85.67% YoY), while the FY2025 annual figure was $11.1 million, down 80.97% from the prior year.
• Share-based Compensation retreated to $2.7 million in Q4 2025 per INBX's latest filing, from $2.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $46.2 million in Q2 2024 and bottomed at $2.4 million in Q1 2025.
• Historically, Share-based Compensation has averaged $9.6 million across 3 years, with a median of $4.7 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 8.01% in 2025 and fell as far as 94.0% in 2025.
• Inhibrx Biosciences' Share-based Compensation stood at $6.4 million in 2023, then plunged by 53.6% to $3.0 million in 2024, then retreated by 8.01% to $2.7 million in 2025.
• Business Quant data shows INBX's Share-based Compensation at $2.7 million in Q4 2025, $2.8 million in Q2 2025, and $2.4 million in Q1 2025.